Catalog No.	PA007197
Product Name	Anti-human CD3e Antibody (Clone: UCHT1) | PA007197
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	cluster of differentiation 3, CD3D, CD3E, CD3G
Summary	The anti-human CD3 monoclonal antibody (clone: UCHT1) was produced in mammalian cells.
Clone	UCHT1
Isotype	Mouse IgG1 kappa
Specificity/Sensitivity	The in vivo grade recombinant mouse monoclonal antibody (clone: UCHT1) specifically binds to the human T cell receptor CD3.
Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the human CD3 protein.
Form Of Antibody	0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin	< 1 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The in vivo grade recombinant anti-human CD3 Mouse IgG1 Kappa monoclonal antibody (clone: UCHT1) is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	Recombinant mouse IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Order Offline	Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Or leave a message with a formal purchase order (PO) Or credit card.

Description

PA007197: Recombinant Anti-human CD3 Monoclonal Antibody (Clone: UCHT1), Mouse IgG1 Kappa, In vivo Grade

Recombinant mouse IgG1 Monoclonal Antibody.

References of Anti-human CD3e Antibody:

1、A Novel Anti-B7-H3 × Anti-CD3 Bispecific Antibody with Potent Antitumor Activity.
Xie, K., et al. Life (Basel). 2022 Jan 21;12(2):157. doi: 10.3390/life12020157. PMID: 35207448.
“Except for MGD009, most of these anti-B7-H3 bsTCEs were synthesized by linking the anti-CD3 antibody and anti-B7-H3 antibody using chemical coupling agents; thus, the size of these antibodies is large, which may negatively affect physicochemical properties such as solubility. …In this study, we aimed to develop a novel format asymmetric anti-B7-H3 × anti-CD3 bispecific antibody (αB7-H3/CD3) based on antibody-binding fragment (Fab) of anti-B7-H3 mAb and single chain variable fragment (scFv) of anti-CD3 mAb (OKT3) and examine its binding activity, cytotoxic potential, and underlying mechanisms against tumor cell lines. …The tumors regressed and were completely eliminated upon treatment with αB7-H3/CD3. …The αB7-H3/CD3 format was developed based on the heterodimeric Fc variant via the knobs-into-holes technique (KIH). …Murine tumor tissues sections were fixed in 4% paraformaldehyde for 20 min at 20 °C and blocked for 10 min. Sections were then stained with anti-CD3 antibody (GB111337, Servicebio, Wuhan, China) overnight at 4 °C, Cy3 conjugated secondary antibody (GB21303, Servicebio, Wuhan, China) for 1 h, and DAPI (G1012, Servicebio, Wuhan, China) for 15 min in the dark. Images were captured with a fluorescence microscope.”

2、Nasal administration of anti-CD3 monoclonal antibody modulates effector CD8+ T cell function and induces a regulatory response in T cells in human subjects.
Chitnis, T., et al. Front Immunol. 2022 Nov 23;13:956907. doi: 10.3389/fimmu.2022.956907. PMID: 36505477.
“The cultures were stimulated with either Foralumab (modified IgG1) or the UCHT1 (IgG1) anti-CD3 mAb. …Upon establishing the assay with increasing amounts of UCHT1 or Foralumab in cultures of either purified CD4 T cells vs all T cells, the data suggests that competition for anti-CD3 Mab does not affect the outcome as poor CD4 T cell viability was observed at all doses of Foralumab as compared to UCHT1 cultures, and only in the cultures that contained all T cells. …In contrast the CD8 T cells in these cultures showed no change in viability, proliferation or frequency of cytokine expression when stimulated with UCHT1 or Foralumab. …We next asked specifically whether CD8 T cells had to be present for Foralumab to exert these unusual effects on CD4 T cell viability and expansion by establishing cultures of FACS-sorted CD4 T cells with and without autologous FACS-sorted CD8 T cells and stimulated with either anti-CD3 Mab. …To determine whether immunologic effects were observed following nasal Foralumab, we stimulated PBMCs with PMA/ionomycin for 4 hours and then stained by flow cytometry for surface and intracellular proteins.”

3、A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
Iizuka, A., et al. Clin Cancer Res. 2019 May 1;25(9):2925-2934. doi: 10.1158/1078-0432.CCR-17-3123. PMID: 30737243.
“In this study, we manufactured anti-B7-H4/CD3 bispecific antibodies (BsAb) based on the Fab and scFv structure. …Because of the recent success of immune checkpoint–blocking antibodies, clinical trials are underway to evaluate their efficacy in various cancers. …In this study, we manufactured B7-H4/CD3 BsAbs based on the antibody-binding fragment (Fab) and single-chain variable fragment (scFv) structure of anti-B7-H4 and anti-CD3 mAbs using a human cell–based protein expression system. …Written informed consent was obtained from all the enrolled patients. All the experiments using clinical samples were carried out in accordance with the approved guidelines. …The mouse anti-human B7-H4 antibody (clone #25) was established in-house as described previously.”

4、The novel CD16A/anti-CD3 bifunctional protein, eCD16A/anti-CD3-BFP, redirects T cell cytotoxicity toward antibody-bound target cells.
Lin, C.-T., et al. Hum Vaccin Immunother. 2025 Dec;21(1):2447141. doi: 10.1080/21645515.2024.2447141. PMID: 39763374.
“To implement this idea, we developed eCD16A/anti-CD3-BFP, a novel bifunctional bridging protein composed of the extracellular domain of the human CD16A high-affinity variant (eCD16A) directly linked to an anti-human CD3 scFv (anti-CD3). …In this work, we performed a proof-of-concept study to demonstrate the function of eCD16A/anti-CD3-BFP and clarify its clinical potential. …To retain high affinity for IgG and prevent proteolytic cleavage of the bifunctional protein, the extracellular domain of haCD16A before the ADAM17-cleavage site was included in eCD16A/anti-CD3-BFP. …To evaluate binding to primary T cells, αβ T cells were incubated with eCD16A/anti-CD3-BFP, followed by anti-CD16 antibody. The results were analyzed with flow cytometry. …PBMCs from healthy donors were incubated with rituximab and eCD16A/anti-CD3-BFP for 144 h. The remaining CD19-positive B cells were quantified by flow cytometry to determine cytotoxicity.”

5、Construction and functional analysis of an anti-human cervical carcinoma/anti-human CD3 single-chain bispecific antibody.
Wu, H., et al. Mol Med Rep. 2016 Jul;14(1):804-10. doi: 10.3892/mmr.2016.5292. PMID: 27220396.
“BsAbs, formed using anti-CD3x antitumor monoclonal antibodies (mcAbs), may trigger T cell major histocompatibility complex to kill and lyse tumor cells. Numerous experiments have demonstrated that CD3-based BsAbs are an efficient type of therapeutic agent for treating tumors. …The present study aimed to establish an anti-human cervical carcinoma/human CD3 scBsAb and detect its biological activity to provide the experimental and theoretical basis for clinical application. …The pMD18-T-anti-CD3 scFv plasmid was constructed according to the methods of a previous study. …The pMD18-T-anti-CD3 scFv and pALMm-CSAs-1 scFv-HSA plasmids were digested by SacI and BamHI, respectively and anti-CD3 scFv was inserted into pALMm-CSAs-1 scFv-HSA using a ligase to form the scBsAb expression vector, pALMm-CSAs-1 scFv-HAS-anti-CD3 scFv. …The iodogen method was used for radioiodination of the antibodies.”

6、MicroRNA expression profiles in human CD3+ T cells following stimulation with anti-human CD3 antibodies.
Sousa, I. G., et al. BMC Res Notes. 2017 Mar 14;10(1):124. doi: 10.1186/s13104-017-2442-y. PMID: 28292330.
“Clinical data have suggested that anti-CD3 therapy is a promising treatment option for autoimmune disease and organ transplantation. …In the presence of co-stimulatory signals, T cells differentiate into specific phenotypic subtypes. …However, OKT3 is a murine monoclonal antibody that displays high toxicity in humans due to its heterologous nature and mitogenic activity. …In this work, we measured changes in miRNA expression in anti-CD3 antibody-stimulated human T cells in vitro in the context of the peripheral blood mononuclear cell (PBMC) milieu. …Approximately 240 ng total RNA isolated from T cells following PBMC stimulation was utilized for cDNA synthesis using an RT2 First Strand Kit (Qiagen).”

7、Injection Effect of Anti-CD3 Monoclonal Antibody on Primo Vessel in Lymph Vessel of Rabbit with Lipopolysaccharide-Induced Inflammation.
Choi, S. H., et al. J Acupunct Meridian Stud. 2022 Feb 28;15(1):37-42. doi: 10.51507/j.jams.2022.15.1.37. PMID: 35770572.
“However, this therapy is administered as an intravenous injection of an anti-CD3 monoclonal antibody, and since it targets all T cells, it induces significant immunosuppression and has side effects such as high fever and chills. …The anti-CD3 human monoclonal antibody ‘Foralumab’ used in this study has the antibody structure of the anti-human CD3 epsilon therapeutic antibody-endotoxin < 1EU/mg manufactured by Creative Biolab. …As determined by the transmission electron microscopy (TEM) image analysis of the junction structure of the anti-CD3 monoclonal antibody, the binding elements were investigated by energy dispersive spectroscopy (EDS). …After preparing a humanized antibody from the anti-CD3 monoclonal antibody, a humanized mouse monoclonal antibody, it was administered to rabbits to maintain the same affinity level to allow animal experiment performance. …Foralumab functions by binding to CD3 in the T cell complex and inhibiting the cytokine storm in three major ways.”

8、Bio-conjugation of anti-human CD3 monoclonal antibodies to magnetic nanoparticles by using cyanogen bromide: A potential for cell sorting and noninvasive diagnosis.
Moradi, N., et al. Int J Biol Macromol. 2021 Dec 1;192:72-81. doi: 10.1016/j.ijbiomac.2021.09.129. PMID: 34606792.
“Indeed, CD3 is expressed on the surface of T cells at all stages of its maturing so it has been utilized to detect lymphocytes in tumor samples. …The present study tried to provide an optimal and cost-effective method for separating TCD3+ cells from PBMC ones, which can be applied to isolate TIL cells for the clinical purposes using CAR-T cell. …The study aimed to assess whether this conjugation method using cyanogen bromide can provide a microbead for utilizing in cell sorting to CAR-T cell therapy in the future and develop targeted contrast agents for MRI imaging, which is a non-invasive way to distinguish CD3+ lymphoma cancer cells. …The sections of tumor were stained to discover if the migrated (to the peripheral part of tumors) iron-positive cells were true of human origin, leading to low signal intensity on MRI. …The limitations of the study include lacking to compare CNBr method with the different conjugation techniques, requiring further research regarding the accuracy of this method, needing to examine more mice in different groups, and developing the method only in the form of exploration.”

For more references about Anti-human CD3e Monoclonal Antibody please contact our scientific support team with message@sydlabs.com.

Syd Labs provides the following in vivo grade recombinant anti-human CD3 monoclonal antibodies:
Muromonab biosimilar, research grade, anti-human CD3 monoclonal antibody (Clone: OKT3)
Teplizumab biosimilar, research grade, anti-human CD3 monoclonal antibody (Clone: OKT3)
Foralumab biosimilar, research grade, anti-human CD3 monoclonal antibody (Clone: OKT3)
Recombinant Anti-human CD3 monoclonal antibody (Clone: OKT3)
Recombinant Anti-human CD3 monoclonal antibody (Clone: SP34-2)
Recombinant Anti-human CD3 monoclonal antibody (Clone: UCHT1)
Recombinant Anti-human CD3 monoclonal antibody (Clone: 12F6)

Syd Labs provides the following in vivo grade recombinant anti-human CD3 bispecific antibodies:
Recombinant Anti-human CD3 / CD3 Bispecific Antibody (Clone: OKT3 / UCHT1)
Recombinant Anti-human CD3 / CD3 Bispecific Antibody (Clone: OKT3 / SP34-2)
Recombinant Anti-human CD3 / CD3 Bispecific Antibody (Clone: SP34-2 / OKT3)

Syd Labs provides the following in vivo grade recombinant anti-mouse CD3 monoclonal antibodies:
Recombinant Anti-mouse CD3e monoclonal antibody (Clone: 145-2C11)
Recombinant Anti-mouse CD3e monoclonal antibody (Clone: 500A2)
Recombinant Anti-mouse CD3 monoclonal antibody (Clone: 17A2)
Recombinant Anti-mouse CD3e monoclonal antibody (Clone: KT3)

Syd Labs provides the following recombinant anti-human CD3 monoclonal antibodies for flow cytometry:
Recombinant Anti-human CD3 monoclonal antibody (Clone: OKT3) for flow cytometry
Recombinant Anti-human CD3 monoclonal antibody (Clone: UCHT1) for flow cytometry
Recombinant Anti-human CD3 monoclonal antibody (Clone: 12F6) for flow cytometry
Recombinant Anti-human CD3 monoclonal antibody (Clone: SP34-2) for flow cytometry

Syd Labs provides the following recombinant anti-mouse CD3 monoclonal antibodies for flow cytometry:
Recombinant Anti-mouse CD3 monoclonal antibody (Clone: 17A2) for flow cytometry
Recombinant Anti-mouse CD3e monoclonal antibody (Clone: 145-2C11) for flow cytometry
Recombinant Anti-mouse CD3e monoclonal antibody (Clone: 500A2) for flow cytometry
Recombinant Anti-mouse CD3e monoclonal antibody (Clone: KT3) for flow cytometry

Anti-human CD3 (UCHT1) from: Recombinant Anti-human CD3e Mouse IgG1 Kappa Monoclonal Antibody (Clone: UCHT1): PA007197 Syd Labs

No more offers for this product!